Do you also own this pharma stock? Goldman Sachs issues ‘sell’ call, find out how much it could fall

Analysts turn cautious on Gland Pharma as Goldman Sachs cuts target to Rs 1,700 and maintains a ‘Sell’ view, while Jefferies and Nomura stay neutral; near-term growth seen muted despite strong long-term fundamentals.